Day 1 | Friday, 24th May 2024
from 09:30
Registration
10:45
Welcome
Scientific committee
11:00-1:00
Session 1
The germinal center reaction as
a catalyst for lymphoma development
Chair
Christian Reinhardt
University Hospital Essen (GER)
11:00
Role of Super-enhancer
Hypermutation in the
Pathogenesis of Diffuse
Large B cell Lymphoma
Riccardo Dalla-Favera,
Columbia University New York (USA)
11:25
Genetics-driven epigenetic disruption
of the germinal center program
in B cell lymphomas
Laura Pasqualucci,
Columbia University New York (USA)
11:50
Aspects of Hodgkin lymphoma biology
Ralf Küppers,
University Hospital Essen (GER)
12:15
Modelling Sporadic Oncogenic Events
in Lympho magenesis
Dinis Calado,
The Francis Crick Institute London (UK)
12:50
Discussion
1:00-2:00
Break
2:00-4:00
Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis
Chair
Peter Borchmann
University Hospital Cologne (GER)
2:00
Mechanisms and therapeutic targeting
of the malignant immune system
Ari M. Melnick,
Weill Cornell Medicine New York (USA)
2:25
Development of small molecules
for epigenetic targets
Othman Al-Sawaf,
Universitätsklinikum Köln (GER)
2:50
Harnessing state switches
in aggressive B-cell lymphoma
Clemens Schmitt,
Charité – University Hospital Berlin (GER)
3:15
DNA-methylation based classification
of lymphomas: A tool to come?
Reiner Siebert,
Ulm University Hospital (GER)
3:40
Remote contribution
Toward the noninvasive characterization
of lymphomas & their microenvironments
Ash A. Alizadeh,
Stanford University / Stanford
Comprehensive Cancer Center (USA)
4:00-6:00
Poster presentation and
Get together
Day 2 | Saturday, 25th May 2024
8:00-10:00
Session 3
Genetic rewiring encodes actionable
vulnerabilities in lymphoma
Chair
Sascha Dietrich
University Hospital Düsseldorf (GER)
8:00
Genetic bases of immune evasion in lymphoma
Margaret Shipp,
Dana Farber/Harvard Cancer Center
Boston (USA)
8:25
Curing aggressive lymphomas
with aggressive combinations
of targeted agents
Louis Staudt,
National Cancer Institute Bethesda (USA)
8:50
Actionable Alterations in LBCL
Björn Chapuy,
Charité University Medicine Berlin (GER)
9:15
Elucidation of Lymphoma Proteogenotypes
Thomas Oellerich,
University Hospital Frankfurt (GER)
9:50
Discussion
10:00-10:30
Break
10:30-12:00
Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis
Chair
Peter Borchmann
University Hospital Cologne (GER)
02:00
Ari M. Melnick
Weill Cornell Medicine New York (USA)
02:25
Stefan Knapp
Goethe-University Frankfurt (GER)
02:50
Clemens Schmitt
Charité – University Hospital Berlin (GER)
03:15
Rainer Siebert
Ulm University Hospital (GER)
09:40
Short talk II
09:50
Discussion
10:30-12:30
Session 4
The next frontier: harnessing the
immune system for lymphoma therapy
Chair
Bastian von Tresckow
University Hospital Essen (GER)
10:30
Chemotherapy free approaches
in first line LBCL – a dream or a reality?
Jason Westin,
University of Texas MD Anderson Cancer
Center Houston (USA)
10:55
Enhancing immunotherapies for germinal
center-derived B cell lymphomas by
EZH2 inhibition
Wendy Béguelin,
Weill Cornell Medicine New York, (USA)
11:20
Multi-omic profiling of CAR T cell
treated aggressive B-cell
lymphoma reveals a CSF1R+
myeloid-monocytic cell
compartment mediating
CAR T cell resistance
Roland Ullrich,
University Hospital Cologne (GER)
11:45
Bispecific T Cell Engagers
in Follicular Lymphoma:
Promises and Path Ahead
Elisabeth Budde,
City of Hope National MedicalCenter Duarte (USA)
12:10
Multimodal and spatially resolved profiling
identifies distinct patterns of T cell infiltration
in nodal B cell lymphoma entities
Sascha Dietrich,
University Hospital Düsseldorf (GER)
12:35
Discussion
12:45-1:45
Break
1:45-3:30
Session 5
Mechanisms of resistance and
definition of high-risk DLBCL
Chair
Ralf Küppers
University Hospital Essen (GER)
1:55
Mechanisms of resistance and
definition of high-risk DLBCL
Andrew Davies,
Southampton General Hospital (UK)
2:20
Overcoming therapy resistance
through single-cell functional precision
medicine approaches
Philipp Staber,
Medical University of Vienna (AUT)
2:45
Autochthonous mouse models of DLBCL
enable in vivo genetic screening and
serve as a platorm for preclinical validation
of actionable vulnerabilities
Christian Reinhardt,
University Hospital Essen (GER)
3:10
Discussion
3:30
Closing remarks
Farewell and Goodbye
Status 05/2024, subject to change.